By Fineline Cube Allist Pharmaceuticals (SHA: 688578) announced that it has signed a strategic collaboration agreement with ArriVent BioPharma, Inc. (NASDAQ: AVBP), obtaining exclusive licenses to research, develop, manufacture, register, and commercialize the antibody-drug conjugate (ADC) AST12608/ARR-002 across Greater China (including Mainland China, Hong Kong, Macao, and Taiwan).
Deal Milestone
| Item | Detail |
|---|---|
| Parties | Allist Pharmaceuticals (SHA: 688578) × ArriVent BioPharma, Inc. (NASDAQ: AVBP) |
| Agreement Type | Strategic collaboration — exclusive regional license |
| Asset | AST12608/ARR-002, antibody-drug conjugate (ADC) |
| Licensed Rights | Research, development, manufacture, registration, and commercialization |
| Territory | Greater China (Mainland China, Hong Kong, Macao, Taiwan) |
| Signing Date | 13 Aug 2026 |
| Regulatory Status | U.S. FDA IND clearance granted 7 May 2026 |
Asset Profile – AST12608/ARR-002
- Molecule: Potential first-in-class MUC16/NaPi2b bispecific, tetravalent ADC
- Targeting Logic: MUC16 and NaPi2b are highly expressed in ovarian and endometrial cancers but show limited expression in normal tissues, making them an ideal combined-target pairing
- Initial Indications: Ovarian cancer and endometrial cancer
- Broader Potential: Therapeutic opportunity across a variety of solid tumors
- Differentiation: The bispecific, tetravalent architecture is designed to enhance tumor selectivity and internalization versus single-target ADCs, a key battleground in the crowded conjugate-drug space
Market Impact & Outlook
- ADC Licensing Boom: Antibody-drug conjugates remain one of oncology’s hottest asset classes, and regional in-licensing into Greater China continues to be a dominant transaction pattern as local companies secure differentiated Western-origin molecules.
- Allist’s Oncology Push: The exclusive license strengthens Allist’s oncology pipeline with a first-in-class candidate already cleared into clinical development by the FDA, compressing its path to China trials.
- ArriVent’s Monetization: The deal extends ArriVent’s partner-funded regionalization strategy, monetizing Greater China rights while retaining global development focus.
- Next Steps: Financial terms, including upfront payment, milestones, and royalties, were not disclosed.
Forward‑Looking Statements
This brief contains forward-looking statements regarding the development and commercialization potential of AST12608/ARR-002 in Greater China. Actual results may differ due to risks including clinical progress, regulatory outcomes, and competitive dynamics in ADC oncology.-Fineline Info & Tech